- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: AC430 is an investigational, potent and selective small molecule inhibitor of janus kinase 2 (JAK2) being developed by Ambit (now owned by Daiichi Sankyo) for the treatment of cancer and autoimmune diseases. AC430 is the (R) optical isomer claimed in patent US8703943 , although the (S) isomer and racemate are also discussed in the patent descriptions.
|Patent US8703943  does not provide inhibitory constants for the compounds vs. janus kinase enzymes. It also suggests that AC430 acts as an antagonist of the adenosine A3 receptor with an IC50 value of 28nM (Ki 26nM).|
|Selectivity at enzymes|
|Key to terms and symbols||Click column headers to sort|